SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group (UNH) is currently a focal point for investors following reports that Berkshire Hathaway exited its entire position, sparking heavy debate between retail traders who view the move as a long-term buy opportunity and skeptics concerned about the stock's recent volatility. Community discussion remains polarized, with many users dismissing the news as outdated portfolio reshuffling while others monitor the stock's resilience against the backdrop of broader healthcare sector trends and potential regulatory developments.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate whether the current price represents a deep-value opportunity or a value trap, with the community closely tracking its pivot into agentic AI orchestration and enterprise integration partnerships. While some participants express frustration over persistent share price weakness and perceived manipulation, others are aggressively accumulating shares, pointing to the company's strong cash position, lack of debt, and potential for long-term growth as the market rotates toward quality AI software.

BioLLM

BioLLM is capturing market attention for its focus on bio-computing and neuron-integrated AI, sparking community excitement about the potential for hybrid intelligence systems. Investors are closely tracking the project's development milestones and upcoming iOS app launch as they discuss its integration with the Solana ecosystem.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is trending due to significant momentum in its pivot toward edge data center infrastructure and high-demand energy management solutions, with investors closely watching the company's progress on scaling its modular edge data center deployments and securing high-value partnerships. The community remains focused on whether Duos can successfully capitalize on the urgent AI industry need for localized compute and power, with active debate surrounding contract backlogs, infrastructure scalability, and the potential for increased analyst and institutional coverage.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is facing intense scrutiny and bearish sentiment as investors weigh the company's decision to slow its weekly Ethereum accumulation against disappointing share price performance compared to broader crypto gains. The community is actively debating the credibility of management's long-term strategy, with many frustrated by persistent dilution and the stock's failure to mirror Ethereum's upside potential.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors focus on upcoming clinical data presentations at the AUA conference, fueling community speculation about a potential FDA approval and the company's broader pipeline. While some community members are frustrated by the stock's consolidation in a tight range and the lack of immediate regulatory updates, others are closely monitoring high institutional accumulation and executive social media activity as indicators of an impending breakout.

Pump.fun

Pump.fun is currently the center of intense community focus, driven by discussions regarding the platform's long-term sustainability, revenue generation, and a wave of new meme coin activity on the Solana network. Community members are actively debating the token's future utility and market momentum, with many users showcasing high conviction through organic engagement while others remain cautious due to the prevalence of speculative risk.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility and intense investor debate ahead of its upcoming earnings report, as shareholders closely monitor the company's financial health, the stability of Elevidys revenue, and progress on its siRNA pipeline. The community is actively scrutinizing the stock's valuation, debating institutional positioning, and reacting to recent leadership shifts at the FDA while expressing frustration over persistent downward price pressure.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

Investors are actively debating whether the software sector is set for a major rotation as capital begins to pivot from high-flying semiconductors into beaten-down SaaS and enterprise software names. While some market participants remain cautious about the long-term impact of generative AI on headcount and legacy software subscriptions, many are viewing current valuations as a compelling entry point for a sector-wide recovery.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is currently experiencing significant price volatility as investors weigh the company's recent regulatory milestones, such as the NRC's approval of its Aurora powerhouse design, against ongoing concerns about cash burn, pre-revenue status, and dilutive share offerings. While the community remains divided between long-term bullishness fueled by AI data center energy demand and skepticism regarding the company's unproven commercial timeline, active traders are closely monitoring upcoming criticality targets and institutional positioning ahead of earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exagen (XGN) Q1 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Exagen Q1 Earnings Call Highlights

The New Spec Supercycle

Momentum traders are once again crowding into emerging growth sectors as artificial intelligence infrastructure, defense modernization, advanced medical technologies, and digital asset finance combine to create one of the market’s most aggressive speculative environments in years. Several names touched new 52-week highs Monday morning alongside major technology leaders including NVIDIA (NASDAQ:NVDA). $ODYS, $KBLB, $DGXX, $BW, $XGN, $MEHA, $NVDA

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Exagen (XGN) delivered earnings and revenue surprises of +29.17% and +4.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) Reports Break-Even Earnings for Q1

AtriCure (ATRC) delivered earnings and revenue surprises of +100.00% and +1.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Zimmer (ZBH) delivered earnings and revenue surprises of +12.57% and +1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (NASDAQ:XGN) Sees Large Decrease in Short Interest

Exagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totaling 729,740 shares, a decline of 52.5% from...

Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Analysts

Exagen Inc. (NASDAQ:XGN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1...

Exagen (NASDAQ:XGN) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded shares of Exagen from a "hold" rating to a "sell" rating in a report on Sunday...

Exagen Inc. (NASDAQ:XGN) Short Interest Update

Exagen Inc. (NASDAQ:XGN - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 1,534,970 shares, an increase of 34.3...

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.19	--	--	N/A
Q1 '26	-$0.23	-$0.17	26.99%	BEAT
Q4 '25	-$0.19	-$0.20	-5.43%	MISSED
Q3 '25	-$0.16	-$0.31	-97.56%	MISSED
Q2 '25	-$0.15	-$0.21	-40.00%	MISSED

XGN
Exagen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest XGN News

XGNExagen Inc